Your browser doesn't support javascript.
loading
The cardiotoxic effects of CAR-T cell therapy: An updated systematic review and meta-analysis.
Mazetto, Roberto A S V; Monteiro, Sarah O N; Bulhões, Elísio; Defante, Maria L R; Antunes, Vanio L J; Balieiro, Caroline Cristine Almeida; Feitoza, Luanna; Ferreira, André L C; Carvalho, Amadeu M; Guida, Camila.
Affiliation
  • Mazetto RASV; Medicine Department, Amazonas State University, Manaus, Brazil.
  • Monteiro SON; Medicine Department, Redentor University Center, Itaperuna, Brazil.
  • Bulhões E; Medicine Department, Faculty of Higher Superior of the Amazon Reunida, Redenção, Brazil.
  • Defante MLR; Medicine Department, Redentor University Center, Itaperuna, Brazil.
  • Antunes VLJ; Medicine Department, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.
  • Balieiro CCA; Medicine Department, Amazonas State University, Manaus, Brazil.
  • Feitoza L; Medicine Department, Fametro University Center, Manaus, Brazil.
  • Ferreira ALC; Medicine Department, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.
  • Carvalho AM; Medicine Department, Ribeirão Preto Medical School of University of São Paulo, Ribeirão Preto, Brazil.
  • Guida C; Division of Cardiology, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil.
Eur J Haematol ; 2024 Aug 22.
Article in En | MEDLINE | ID: mdl-39171519
ABSTRACT

BACKGROUND:

Chimeric antigen receptor T-cell (CAR-T) therapy has shown promise in treating hematologic malignancies, yet its potential cardiotoxic effects require thorough investigation.

OBJECTIVES:

We aim to conduct a systematic review and meta-analysis to examine the cardiotoxic effects of CAR-T therapy in adults with hematologic malignancies.

METHODS:

We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for studies reporting cardiovascular outcomes, such as arrhythmias, heart failure, and reduced left ventricle ejection fraction (LVEF).

RESULTS:

Our analysis of 20 studies involving 4789 patients revealed a 19.68% incidence rate of cardiovascular events, with arrhythmias (7.70%), heart failure (5.73%), and reduced LVEF (3.86%) being the most prevalent. Troponin elevation was observed in 23.61% of patients, while NT-Pro-BNP elevation was observed in 9.4. Subgroup analysis showed higher risks in patients with pre-existing conditions, such as atrial arrhythmia (OR 3.12; p < .001), hypertension (OR 1.85; p = .002), previous heart failure (OR 3.38; p = .003), and coronary artery disease (OR 2.80; p = .003).

CONCLUSION:

Vigilant cardiovascular monitoring is crucial for patients undergoing CAR-T therapy to enhance safety and treatment efficacy.Novelty Statements.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2024 Document type: Article Affiliation country: Brazil Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2024 Document type: Article Affiliation country: Brazil Country of publication: United kingdom